Table 2. Baseline characteristics and treatment results in patients receiving an IFN-free DAA regimen.
| IFN-free regimens | Complete cohort | GZR/EBR | GLE/PIB | OBV/PTV/r | OBV/PTV/r | SOF±RBV | SOF+DCV | SOF/LDV | SOF+SIM | SOF/VEL/ | SOF/VEL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of therapies | n = 878 (%) | n = 30 (%) | n = 47 (%) | n = 21 (%) | +DSV, n = 84 (%) | n = 49 (%) | n = 34 (%) | n = 449 (%) | n = 26 (%) | VOX, n = 14 (%) | n = 124 (%) |
| Age (y, mean ± SD) | 53.1 ± 12.9 | 56.6 ± 14.4 | 50.0 ± 11.0 | 48.7 ± 13.7 | 59.2 ± 12.5 | 55.9 ± 11.2 | 55.3 ± 8.7 | 52.1 ± 13.2 | 57.1 ± 10.6 | 59.4 ± 11.3 | 50.1 ± 12.3 |
| Sex (male/female) | 486 (55) / 392 (45) | 23 (77) / 7 (23) | 26 (55) / 21 (45) | 14 (66)/ 7 (33) | 42 (50) / 42 (50) | 28 (57) / 21 (43) | 23 (68) / 11 (32) | 237 (53) / 212 (47) | 18 (69) / 8 (31) | 11 (79) / 3 (21) | 80 (65) / 44 (35) |
| Transplanted patients | 54 (6) | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 14 (29) | 5 (15) | 22 (5) | 9 (35) | 1 (7) | 2 (2) |
| People with HIV | 38 (4) | 1 (3) | 0 (0) | 0 (0) | 1 (1) | 4 (8) | 5 (15) | 15 (3) | 0 (0) | 0 (0) | 12 (10) |
| Liver cirrhosis | 254 (29) | 12 (40) | 1 (2) | 2 (10) | 23 (27) | 13 (27) | 22 (65) | 117 (26) | 18 (69) | 8 (57) | 38 (31) |
| Child-Pugh score A/B/C | 180/71/3 | 9/3/0 | 1/0/0 | 2/0/0 | 21/2/0 | 8/5/0 | 12/9/1 | 87/29/1 | 9/9/0 | 3/5/0 | 28/9/1 |
| IFN-experienced | 267 (30) | 1 (3) | 5 (11) | 4 (19) | 21 (25) | 28 (57) | 18 (53) | 147 (33) | 14 (54) | 6 (43) | 23 (19) |
| HCV Genotype | |||||||||||
| 1 (a/b/c/unclassified) | 616 [70] (270/327/3/16) | 28 [93] (6/22/0/0) | 25 [53] (16/8/0/1) | 0 (0) | 82 [98] (6/76/0/0) | 7 [14] (2/5/0/0) | 17 [50] (7/9/0/1) | 414 [92] (209/190/2/13) | 20 [77] (7/11/1/1) | 9 [64] (6/3/0/0) | 14 [11] (11/3/0/0) |
| 2 | 44 (5) | 0 (0) | 6 (13) | 0 (0) | 0 (0) | 25 (51) | 0 (0) | 0 (0) | 0 (0) | 2 (14) | 11 (9) |
| 3 | 148 (17) | 0 (0) | 10 (21) | 0 (0) | 0 (0) | 12 (24) | 15 (44) | 14 (3) | 2 (8) | 2 (14) | 93 (75) |
| 4 | 58 (7) | 2 (7) | 4 (9) | 21 (100) | 1 (1) | 3 (6) | 2 (6) | 17 (4) | 4 (15) | 1 (7) | 3 (2) |
| 5 | 2 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 6 | 3 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (1) | 0 (0) | 0 (0) | 0 (0) |
| 1/3 coinfection | 2 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | 0 (0) | 1 (1) |
| 2k/1b | 2 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2) |
| Unknown | 3 (0) | 0 (0) | 1 (2) | 0 (0) | 1 (1) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Outcome parameters | |||||||||||
| Lost to follow-up | 78 (9) | 6 (20) | 1 (2) | 4 (19) | 5 (6) | 2 (4) | 1 (3) | 48 (11) | 1 (4) | 0 (0) | 10 (8) |
| Documented 12-wk FU after EoT | 800 (91) | 24 (80) | 46 (98) | 17 (81) | 79 (94) | 47 (96) | 33 (97) | 401 (89) | 25 (96) | 14 (100) | 114 (92) |
| Virological relapse | 48 (6) | 1 (4) | 0 (0) | 0 (0) | 2 (3) | 8 (17) | 6 (18) | 23 (6) | 5 (20) | 1 (7) | 2 (2) |
| SVR | 752 (94) | 23 (96) | 46 (100) | 17 (100) | 77 (97) | 39 (83) | 27 (82) | 378 (94) | 20 (80) | 13 (93) | 112 (98) |
| GT 1a | 212/231 (92) | 3/4 (75) | 16/16 (100) | n/a | 4/5 (80) | 2/2 (100) | 3/6 (50) | 168/178 (94) | 4/6 (67) | 5/6 (83) | 7/8 (88) |
| GT 1b | 295/306 (96) | 18/18 (100) | 8/8 (100) | n/a | 71/72 (99) | 3/5 (60) | 9/9 (100) | 171/177 (97) | 9/11 (82) | 3/3 (100) | 3/3 (100) |
| GT 2 | 35/40 (88) | n/a | 5/5 (100) | n/a | n/a | 19/24 (79) | n/a | n/a | n/a | 2/2 (100) | 9/9 (100) |
| GT 3 | 136/142 (96) | n/a | 10/10 (100) | n/a | n/a | 10/11 (91) | 12/15 (80) | 12/14 (86) | 2/2 (100) | 2/2 (100) | 88/89 (99) |
| GT 4 | 48/51 (94) | 2/2 (100) | 4/4 (100) | 17/17 (100) | 1/1 (100) | 3/3 (100) | 2/2 (100) | 12/15 (80) | 4/4 (100) | 1/1 (100) | 2/2 (100) |
| GT 5 | 2/2 (100) | n/a | 1/1 (100) | n/a | n/a | 1/1 (100) | n/a | n/a | n/a | n/a | n/a |
| GT 6 | 2/3 (67) | n/a | n/a | n/a | n/a | n/a | n/a | 2/3 (67) | n/a | n/a | n/a |
SVR rates were calculated taking all patients with a documented 12-week FU after EoT into account. Values shown are percentages and counts and mean values with the corresponding standard deviation.
Abbreviations: DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; EoT, end of treatment; FU, follow-up; GLE, glecaprevir; GZR, grazoprevir; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon; LDV, ledipasvir; n/a, not applicable; OBV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; SD, standard deviation; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response; VEL, velpatasvir; VOX, voxilaprevir.